What is the recommended treatment for urge urinary incontinence?

Treatment for Urge Incontinence

Bladder training is mandatory as the initial treatment for all adults with urge urinary incontinence before any medication is started. 1, 2

Step 1: Mandatory Behavioral Therapy (Before Any Medication)

Bladder training must be implemented first with scheduled voiding intervals that are progressively lengthened to retrain bladder capacity. 1, 2 This is a strong recommendation with moderate-quality evidence from the American College of Physicians. 1

Adjunctive Lifestyle Modifications to Implement Concurrently:

• Weight loss and exercise for obese patients reduce urgency incontinence episodes by 42% versus 26% in controls when combined with bladder training. 1, 2
• Reduce fluid intake by approximately 25% to lower urinary frequency and urgency. 2
• Caffeine reduction decreases voiding frequency. 2

Critical pitfall: Never bypass bladder training and start medication directly—this contradicts evidence-based guidelines and exposes patients to unnecessary adverse effects. 2, 3

Step 2: Pharmacologic Therapy (Only After Bladder Training Fails)

Pharmacologic treatment should only be initiated after bladder training has been unsuccessful. 1, 2 This is a strong recommendation with high-quality evidence. 1

First-Line Antimuscarinic Selection (Based on Tolerability):

Tolterodine or darifenacin are the optimal first-line antimuscarinics because discontinuation rates are comparable to placebo and they have superior tolerability profiles. 2, 4

Solifenacin shows the lowest risk of discontinuation due to adverse effects among antimuscarinics (Number Needed to Treat = 9 for achieving continence). 2, 4

Antimuscarinics to Avoid:

Oxybutynin should be avoided as a first-line agent because it has the highest discontinuation rate from adverse effects (NNTH = 16) and carries significant risk of cognitive impairment, especially in older adults. 2, 4

Fesoterodine has the poorest tolerability (NNTH = 7 for adverse effects), making it a less favorable option. 2, 4

Alternative: Beta-3 Agonist

Mirabegron produces markedly fewer anticholinergic side effects (dry mouth) than antimuscarinics, with dry-mouth incidence similar to placebo and 3–5× lower than tolterodine. 2

Mirabegron should be preferred in patients with cognitive concerns, dementia risk, or polypharmacy (≥7 medications). 2, 4

Step 3: Treatment Algorithm for Medication Selection

When bladder training fails:

• For patients without cognitive concerns or polypharmacy (<7 concurrent medications): Start tolterodine, darifenacin, or solifenacin. 2
• For patients with cognitive concerns, dementia risk, or polypharmacy (≥7 medications): Prefer tolterodine, darifenacin, or mirabegron. 2, 4
• Base choice on tolerability, adverse-effect profile, ease of use, and cost—efficacy is comparable across agents. 1

Step 4: Combination Therapy for Refractory Cases

If monotherapy fails, combination of an antimuscarinic with a beta-3 agonist may be used. 1, 2 The most robust data support solifenacin 5 mg + mirabegron 25–50 mg, which provides superior efficacy to either agent alone. 2

Combination therapy yields additive reductions in incontinence episodes but modestly increases adverse events (dry mouth, constipation, urinary retention). 2

Critical Safety Considerations and Contraindications

Antimuscarinics must not be used in patients with narrow-angle glaucoma unless approved by an ophthalmologist. 2, 3

Use extreme caution in patients with impaired gastric emptying or history of urinary retention. 1, 2

Concurrent solid oral potassium chloride is contraindicated because antimuscarinics increase potassium absorption. 2, 3

Discuss the potential risk for developing dementia and cognitive impairment with all patients prescribed antimuscarinic medications, as this may be cumulative and dose-dependent. 1

Common Adverse Effects

All antimuscarinics commonly cause dry mouth, constipation, and blurred vision, but these effects are less frequent with tolterodine and darifenacin than with oxybutynin. 1, 2

Adherence to antimuscarinics is generally poor due to side effects, making tolerability the primary differentiating factor for drug selection. 2, 4

Special Considerations for Elderly Patients

Age does not alter the efficacy of pharmacologic treatment, but older adults are more susceptible to central nervous system adverse effects. 2, 4

Tolterodine and darifenacin remain preferred in elderly females, showing discontinuation rates comparable to placebo. 2, 4

What NOT to Do

Systemic pharmacologic therapy should not be used for stress incontinence—it is ineffective and contraindicated. 1, 2, 3

Identify and treat underlying contributors (urinary tract infection, metabolic disturbances, excess fluid intake, offending medications) before escalating to pharmacologic therapy. 1, 2